checkAd
    Startseite > Aktien > Edgewise Therapeutics > Nachrichten
    Edgewise Therapeutics Aktie
    20,000
     
    USD
    -4,26 %
    -0,890 USD
    Letzter Kurs 02:00:00 Nasdaq
    19,980
     
    USD
    800 STK
    Geldkurs 09.05.24
    19,990
     
    USD
    100 STK
    Briefkurs 09.05.24
    ISIN: US28036F1057 · WKN: A2QRZ8 · SYM: EWTX · USA

    Neueste Nachrichten

    Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
    09.05.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
    07.05.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
    06.05.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
    23.04.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
    15.04.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
    28.03.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
    27.03.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
    05.03.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
    28.02.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
    22.02.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
    13.02.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
    19.01.24 · Business Wire (engl.) · Edgewise Therapeutics